<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="191545">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00599118</url>
  </required_header>
  <id_info>
    <org_study_id>8271</org_study_id>
    <nct_id>NCT00599118</nct_id>
  </id_info>
  <brief_title>Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation</brief_title>
  <official_title>Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish a genebank repository of blood samples and data to
      generate information about the hereditary (genetic) basis of atrial fibrillation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood samples and data will be collected from subjects with atrial fibrillation and normal
      controls. The primary aim of future research using these samples is to identify mechanisms
      and pathogenesis of atrial fibrillation. Through this information, we hope to identify
      targets for new therapies and improve knowledge and understanding of atrial fibrillation.
      Identification of disease genes could improve strategies that prevent progression of atrial
      fibrillation to more persistent disease.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2005</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial fibrillation</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>atrial fibrillation</arm_group_label>
    <description>Atrial fibrillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Control subjects with no atrial fibrillation</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, serum, buffy coat, DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with atrial fibrillation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Atrial Fibrillation group:

          -  Male or female at least 18 years old

          -  Subjects with a history of or current Atrial Fibrillation

          -  Subjects able to give informed consent

        Inclusion Criteria for Controls:

          -  Male or female at least 18 years old

          -  Subjects with no history of Atrial Fibrillation

          -  Subjects able to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mina K Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinical Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <lastchanged_date>June 1, 2010</lastchanged_date>
  <firstreceived_date>January 10, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Mina K. Chung, MD</name_title>
    <organization>Cleveland Clinic Foundation</organization>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
